New nasal spray vaccine for RSV shows promise in young children
NCT ID NCT05687279
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a live, weakened RSV vaccine given as a nasal spray to infants and toddlers aged 6 to 24 months in Puerto Rico. The main goal was to see if the vaccine virus spreads from vaccinated children to others in the same household or daycare, and to check how long the virus is shed. Researchers also looked at the vaccine's safety and how well it triggers an immune response. The study included 80 healthy children and compared the vaccine to a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
live attenuated respiratory syncytial virus (RSV) vaccine given as a nasal spray
What this could lead to
If successful, this could lead to a safe RSV vaccine for infants that does not spread to others, helping protect young children from severe RSV disease.
What could go wrong
This is an early-phase study with only 80 participants, so results may not apply to larger populations. The vaccine virus might still spread or cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number : 6300001
San Juan, 00918, Puerto Rico
-
Investigational Site Number : 6300002
Carolina, 984, Puerto Rico
-
Investigational Site Number : 6300003
Guayama, 00784, Puerto Rico
-
Investigational Site Number : 6300004
Bayamón, 00960, Puerto Rico
-
Meridian Clinical Research Norfolk Site Number : 8400003
Norfolk, Nebraska, 68701, United States
-
Velocity Clinical Research, Omaha Site Number : 8400001
Omaha, Nebraska, 68134, United States